Expert Perspectives & Insights into the Evolving Treatment of Refractory Metastatic Colorectal Cancer

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

Key safety considerations for the use of fruquintinib are explored.

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

Side effect profiles driven by fruquintinib use are discussed.

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

Multiple abstracts from ESMO 2023, including a focus on tumor location, are highlighted.

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Key opportunities to improve the mCRC treatment landscape are illustrated by the expert panelists.

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.